Sutent Shows Benefit In Rare Pancreatic Cancer; Pfizer Stops Phase III Early
This article was originally published in Pharmaceutical Approvals Monthly
Pfizer stopped a Phase III trial for its cancer drug Sutent (sunitinib) early after the data safety monitoring board said the compound showed significant benefit in a rare form of pancreatic cancer, the company announced March 12
You may also be interested in...
With a lot of determination and a lot of licensing, Pfizer has managed to pack its oncology pipeline with novel mechanisms. Now the company is trying to innovate its business organization to make the most of what it has
Angiogenesis inhibitor SU11248 shows significant efficacy in Gleevec-resistant gastrointestinal stromal tumors; Pfizer plans NDA submission for GIST and renal cell carcinoma by end of 2005. A Phase III trial in second-line renal cell carcinoma is ongoing.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.